Lazard Asset Management LLC Grows Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Lazard Asset Management LLC boosted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 13.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,110 shares of the company's stock after acquiring an additional 3,303 shares during the quarter. Lazard Asset Management LLC owned 0.09% of Medpace worth $9,337,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC raised its position in Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company's stock worth $6,603,000 after acquiring an additional 8,275 shares in the last quarter. Sanctuary Advisors LLC grew its stake in Medpace by 20.5% in the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock valued at $1,738,000 after buying an additional 844 shares during the last quarter. SYM FINANCIAL Corp bought a new position in Medpace in the 4th quarter valued at about $320,000. Tokio Marine Asset Management Co. Ltd. bought a new stake in shares of Medpace during the fourth quarter worth approximately $9,335,000. Finally, Truist Financial Corp increased its position in Medpace by 166.2% during the 4th quarter. Truist Financial Corp now owns 10,277 shares of the company's stock worth $3,414,000 after buying an additional 6,417 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of NASDAQ MEDP traded down $0.92 during midday trading on Monday, hitting $304.74. 130,324 shares of the stock traded hands, compared to its average volume of 350,526. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $459.77. The business has a 50 day moving average price of $304.24 and a two-hundred day moving average price of $327.86. The company has a market cap of $8.76 billion, a PE ratio of 24.13, a P/E/G ratio of 3.81 and a beta of 1.55.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $3.06 by $0.61. The firm had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter in the prior year, the company posted $3.20 earnings per share. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the sale, the director now directly owns 2,998 shares of the company's stock, valued at approximately $904,856.36. This trade represents a 36.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 20.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MEDP. Leerink Partners started coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and decreased their target price for the company from $370.00 to $328.00 in a report on Monday, April 14th. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research report on Monday, March 24th. Robert W. Baird cut their target price on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Finally, William Blair reissued a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $349.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.